Population pharmacokinetic modelling of non-linear brain distribution of morphine: Influence of active saturable influx and P-glycoprotein mediated efflux

British Journal of Pharmacology

Volumn 151, Issue 5, 2007, Pages 701-712

  Groenendaal, D ^a,d   Freijer, J ^b   De Mik, D ^a   Bouw, M R ^c   Danhof, M ^a,b   De Lange, E C M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LAP and P Consultants BV   (Netherlands)

^c GLAXOSMITHKLINE   (United Kingdom)

^d Astellas Pharma Global Development   (Netherlands)

Author keywords

Microdialysis; Morphine; P glycoprotein; Population pharmacokinetic modelling

Indexed keywords

ELACRIDAR; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MORPHINE;

ACTIVE TRANSPORT; ANIMAL EXPERIMENT; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; EXTRACELLULAR FLUID; MALE; MICRODIALYSIS; NONHUMAN; NONLINEAR SYSTEM; PASSIVE TRANSPORT; POPULATION MODEL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SENSITIVITY ANALYSIS; TRANSPORT KINETICS;

ACRIDINES; ALGORITHMS; ANALGESICS, OPIOID; ANIMALS; BLOOD GAS ANALYSIS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; HYPNOTICS AND SEDATIVES; MALE; MICRODIALYSIS; MIDAZOLAM; MORPHINE; NONLINEAR DYNAMICS; P-GLYCOPROTEIN; POPULATION; RATS; RATS, WISTAR; RESPIRATION, ARTIFICIAL; TETRAHYDROISOQUINOLINES;

EID: 34347353175     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707257     Document Type: Article

References (38)

1. Beal SL, Sheiner LB (1999). NONMEM Users Guide. San Francisco, CA.
2. Bouw MR, Gardmark M, Hammarlund-Udenaes M (2000). Pharmacokinetic- pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats - a microdialysis study. Pharm Res 17: 1220-1227.
3. Bouw MR, Hammarlund-Udenaes M (1998). Methodological aspects of the use of a calibrator in in vivo microdialysis-further development of the retrodialysis method. Pharm Res 15: 1673-1679.
4. Bouw MR, Xie R, Tunblad K, Hammarlund-Udenaes M (2001). Blood-brain barrier transport and brain distribution of morphine-6-glucuronide in relation to the antinociceptive effect in rats - pharmacokinetic/pharmacodynamic modelling. Br J Pharmacol 134: 1796-1804.
5. Bungay PM, Morrison PF, Dedrick RL (1990). Steady-state theory for quantitative microdialysis of solutes and water in vivo and in vitro. Life Sci 46: 105-119.
6. Coughtrie MW, Ask B, Rane A, Burchell B, Hume R (1989). The enantioselective glucuronidation of morphine in rats and humans. Evidence for the involvement of more than one UDP-glucuronosyltransferase isoenzyme. Biochem Pharmacol 38: 3273-3280.
7. Cox EH, Van Hemert JG, Tukker EJ, Danhof M (1997). Pharmacokinetic- pharmacodynamic modelling of the EEG effect of alfentanil in rats. J Pharmacol Toxicol Methods 38: 99-108.
8. Cox EH, Veyrat-Follet C, Beal SL, Fuseau E, Kenkare S, Sheiner LB (1999). A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-to-event pharmacodynamic responses: the antiemetic effect of ondansetron. J Pharmacokinet Biopharm 27: 625-644.
9. Dagenais C, Graff CL, Pollack GM (2004). Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 67: 269-276.
10. de Lange EC, Danhof M (2002). Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 41: 691-703.
11. Duffull SB, Aarons L (2000). Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers. Eur J Pharm Sci 10: 275-284.
12. Ekblom M, Gardmark M, Hammarlund-Udenaes M (1993). Pharmacokinetics and pharmacodynamics of morphine-3-glucuronide in rats and its influence on the antinociceptive effect of morphine. Biopharm Drug Dispos 14: 1-11.
13. Gardmark M, Ekblom M, Bouw R, Hammarlund-Udenaes M (1993). Quantification of effect delay and acute tolerance development to morphine in the rat. J Pharmacol Exp Ther 267: 1061-1067.
14. Groenendaal D, Blom-Roosemalen MC, Danhof M, Lange EC (2005). High-performance liquid chromatography of nalbuphine, butorphanol and morphine in blood and brain microdialysate samples: application to pharmacokinetic/ pharmacodynamic studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci 822: 230-237.
15. Groenendaal D, Freijer J, de Mik D, Bouw MR, Danhof M, Lange EC (2007). Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG. Br J Pharmacol 151: 713-720 (this issue).
16. Hammarlund-Udenaes M, Paalzow LK, de Lange EC (1997). Drug equilibration across the blood-brain barrier - pharmacokinetic considerations based on the microdialysis method. Pharm Res 14: 128-134.
17. Henthorn TK, Liu Y, Mahapatro M, Ng KY (1999). Active transport of fentanyl by the blood-brain barrier. J Pharmacol Exp Ther 289: 1084-1089.
18. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL (1998). Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm Res 15: 599-605.
19. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL (1999a). Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos 27: 827-834.
20. Letrent SP, Polli JW, Humphreys JE, Pollack GM, Brouwer KR, Brouwer KL (1999b). P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells. Biochem Pharmacol 58: 951-957.
21. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ et al. (2002). Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303: 1029-1037.
22. Mandema JW, Tukker E, Danhof M (1991). Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. Br J Pharmacol 102: 663-668.
23. Moghaddam B, Bunney BS (1989). Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine. J Neurochem 53: 652-654.
24. Olson RJ, Justice Jr JB (1993). Quantitative microdialysis under transient conditions. Anal Chem 65: 1017-1022.
25. Salem A, Hope W (1997). Role of morphine glucuronide metabolites in morphine dependence in the rat. Pharmacol Biochem Behav 57: 801-807.
26. Schinkel AH, Wagenaar E, Mol CA, van Deemter L (1996). P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97: 2517-2524.
27. Schinkel AH, Wagenaar E, van Deemter L, Mol CA, Borst P (1995). Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96: 1698-1705.
28. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987). Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-7738.
29. Tolle-Sander S, Rautio J, Wring S, Polli JW, Polli JE (2003). Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res 20: 757-764.
30. Tunblad K, Jonsson EN, Hammarlund-Udenaes M (2004). Morphine blood-brain barrier transport is influenced by probenecid co-administration. Pharm Res 20: 618-623.
31. Upton RN, Ludbrook GL, Grant C, Doolette DJ (2000). The effect of altered cerebral blood flow on the cerebral kinetics of thiopental and propofol in sheep. Anesthesiology 93: 1085-1094.
32. van Bree JB, de Boer AG, Danhof M, Ginsel LA, Breimer DD (1988). Characterization of an 'in vitro' blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J Pharmacol Exp Ther 247: 1233-1239.
33. van Crugten JT, Somogyi AA, Nation RL, Reynolds G (1997). Concentration-effect relationships of morphine and morphine-6 beta-glucuronide in the rat. Clin Exp Pharmacol Physiol 24: 359-364.
34. Wagner JG (1974). A safe method for rapidly achieving plasma concentration plateaus. Clin Pharmacol Ther 16: 691-700.
35. Wandel C, Kim R, Wood M, Wood A (2002). Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96: 913-920.
36. Wu D, Kang YS, Bickel U, Pardridge WM (1997). Blood-brain barrier permeability to morphine-6-glucuronide is markedly reduced compared with morphine. Drug Metab Dispos 25: 768-771.
37. Xie R, Hammarlund-Udenaes M, de Boer AG, de Lange EC (1999). The role of P-glycoprotein in blood-brain barrier transport of morphine: transcortical microdialysis studies in mdr1a (-/-) and mdr1a (+/+) mice. Br J Pharmacol 128: 563-568.
38. Yano Y, Beal SL, Sheiner LB (2001). Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28: 171-192.